Liver Cancer
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 21, 2006; 12(23): 3707-3715
Published online Jun 21, 2006. doi: 10.3748/wjg.v12.i23.3707
Table 1 Baseline patient characteristics of the four evaluated treatment subgroups
PEI alone
Sec PEI after bestsupp. care
TACE-PEIcombinat.
Sec PEI, afterTACE
P-value
(2) n = 34(4) n = 20(1) n = 37(3) n = 10
Child-PughA14 (41%)17 (35%)18 (49%)6 (60%)
B14 (41%)10 (50%)19 (51%)4 (40%)
C6 (18%)3 (15%)0 (0%)0 (0%)
Okuda112 (36%)2 (10%)16 (46%)6 (67%)0.05
220 (61%)14 (74%)16 (46%)3 (33%)
31 (3%)3 (16%)3 (8%)0 (0%)
Gendermale27 (80%)19 (95%)33 (89%)7 (70%)NS
Portal vein thrombyes1 (3%)7 (35%)9 (26%)1 (10%)0.02
Ascitesyes12 (35%)13 (65%)16 (44%)1 (10%)0.03
No of tumors14 (12%)3 (15%)5 (13%)2 (20%)0
28 (23%)3 (15%)4 (11%)1 (10%)
313 (38%)1 (5%)2 (6%)2 (20%)
47 (21%)0 (0%)9 (24%)0 (0%)
52 (6%)1 (5%)17 (46%)1 (10%)
multiple0 (0%)12 (60%)0 (0%)4 (40%)
Tumor sizemm41 (14)268 (39)52 (20)75 (32)0
No of PEIn2.3 (1.6)3 (2.8)2.6 (1.2)3.3 (2.3)NS
Weightkg75 (12)75 (10)77 (16)78 (18)NS
AFPng/mL235 (515)5743 (15 910)257 (476)28 (44)NS
CRPmg/L65 (61)92 (68)97 (73)83 (58)NS
Bilirubinµmol/L35 (24)36 (36)23 (21)13 (7)0.008
CHEmU/mL2.8 (1.6)2.6 (1.4)3.7 (1.4)4.6 (1.1)0.005
LDHU/L226 (77)218 (41)218 (58)198 (27)NS
Proteing/L73 (7)74 (8)73 (6)71 (4)NS
ASTU/L43 (45)39 (26)37 (41)15 (6)0.01
ALTU/L37 (34)33 (24)35 (31)14 (5)NS
APU/L204 (98)254 (125)212 (108)320 (412)NS
G-GTU/L105 (75)107 (75)153 (172)123 (203)NS
Leukocytes1000/μL5.6 (2.2)5.5 (1.4)6.0 (2.5)6.3 (1.8)NS
QUICK%75 (18)79 (13)85 (18)88 (21)NS
Thrombocytes1000/μL120 (56)145 (76)124 (62)213 (115)NS
Creatinineµmol/L82 (38)106 (120)78 (35)72 (17)NS

  • Citation: Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, Chavan A, Rosenthal H, Kubicka S, Krusche S, Merkesdal S, Galanski M, Manns MP, Bleck JS. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol 2006; 12(23): 3707-3715
  • URL: https://www.wjgnet.com/1007-9327/full/v12/i23/3707.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v12.i23.3707